Remoxiprida [Inn-Spanish] en es it fr

Remoxiprida [Inn-Spanish] Brand names, Remoxiprida [Inn-Spanish] Analogs

Remoxiprida [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Remoxiprida [Inn-Spanish] Chemical_Formula


Remoxiprida [Inn-Spanish] RX_link

No information avaliable

Remoxiprida [Inn-Spanish] fda sheet

Remoxiprida [Inn-Spanish] msds (material safety sheet)

Remoxiprida [Inn-Spanish] Synthesis Reference

No information avaliable

Remoxiprida [Inn-Spanish] Molecular Weight

371.269 g/mol

Remoxiprida [Inn-Spanish] Melting Point

No information avaliable

Remoxiprida [Inn-Spanish] H2O Solubility

74 mg/L

Remoxiprida [Inn-Spanish] State


Remoxiprida [Inn-Spanish] LogP


Remoxiprida [Inn-Spanish] Dosage Forms


Remoxiprida [Inn-Spanish] Indication

For the treatment of schizophrenia.

Remoxiprida [Inn-Spanish] Pharmacology

Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act specifically on the dopamine D2 receptor. As a consequence, several undesired side effects can occur. Patients often feel they are not taking any antipsychotic drug. It has a potent affinity for the sigma receptor, but it is unclear whether it is a sigma agonist or antagonist. The contribution of this property to its clinical profile is unknown. Blocking the D2 dopamine receptor is known to cause relapse in patients that have achieved remission from depression, and such blocking also counteracts the effectiveness of SSRI medication.

Remoxiprida [Inn-Spanish] Absorption

Rapidly absorbed. Absolute bioavailability is 90%.

Remoxiprida [Inn-Spanish] side effects and Toxicity

No information avaliable

Remoxiprida [Inn-Spanish] Patient Information

No information avaliable

Remoxiprida [Inn-Spanish] Organisms Affected

Humans and other mammals